FIELD: medicine.
SUBSTANCE: group of inventions refers to the proliferative disease treatment. Disclosed is a pharmaceutical combination containing phosphatidyl inositol 3-kinase - (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide inhibitor 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof and c-Met receptor tyrosine kinase inhibitor - 2-fluoro-N-methyl-4-[7-quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide or a pharmaceutically acceptable salt thereof - in therapeutically effective amounts for use in treating a proliferative disease. Also disclosed are a pharmaceutical composition, a method of treating a proliferative disease, method of inhibiting the formation of metastases in an individual with cancer, using a combination to produce a drug for treating a proliferative disease.
EFFECT: group of inventions provides a synergetic effect of said combination in treating a proliferative disease.
19 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
| SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | 2012 |
|
RU2607944C2 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2411242C2 |
| COMBINED THERAPY | 2015 |
|
RU2695230C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2383545C2 |
| COMBINATIONS OF HSP90 INHIBITOR | 2009 |
|
RU2519673C2 |
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | 2014 |
|
RU2680246C1 |
